Brazil health regulation "bundling" triggers Anvisa rethink
This article was originally published in Clinica
Executive Summary
Brazil's ongoing devolution of healthcare regulation is seeing state and municipal healthcare authorities tending to merge the five tiers of health-related surveillance. So said Maria Cecília Martins Brito, director of national agency Anvisa, last week, at the end of a two-day conference of healthcare leaders, held to "discuss the necessity and the options" for better linking the healthcare elements at a local level. The five components of Brazil's health-related regulation are: healthcare, epidemiology, environmental, nutritional and health & safety at work.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.